Header

Header

Header

Lipid Nanoparticle (LNP) Encapsulation for siRNA, ASO & mRNA Programs

Custom LNP encapsulation support for siRNA, ASO, mRNA, and oligonucleotide delivery programs.

Microfluidic Mixing High EE% DLS Size & PDI Zeta Potential TFF / Dialysis Exchange Sterility • Endotoxin RUO → GMP-like

End-to-end LNP formulation and encapsulation support

Lipid nanoparticles (LNPs) are clinically validated delivery systems for siRNA, mRNA, and therapeutic oligonucleotides.

Bio-Synthesis provides end-to-end custom lipid nanoparticle formulation and microfluidic LNP encapsulation services to support reproducible particle size, controlled PDI, high encapsulation efficiency, and scalable oligonucleotide delivery workflows for siRNA, ASO, and mRNA programs.

Overview / Capabilities

LNP formulation support

Custom LNP encapsulation workflows built around your payload, target size, buffer, and QC requirements.

  • Microfluidic mixing workflows
  • siRNA, ASO, and mRNA payloads
  • Custom lipid and buffer conditions
  • TFF or dialysis buffer exchange
Oligonucleotide payload encapsulated within LNP

Concept: oligonucleotide payload enters and is retained within the lipid nanoparticle.

Key Specifications

Typical LNP project targets

  • Modalities: siRNA, ASO, mRNA
  • Size Range: 60–120 nm
  • PDI: typically ≤ 0.20
  • EE%: ≥ 85%, program-dependent
  • QC: DLS, EE%, zeta, LAL
  • Supply: RUO to GMP-like lots

Microfluidic Precision

FRR/TFR control for consistent particle size and PDI.

Flexible Formulation

Custom lipid ratios, buffers, and nucleic acid chemistries.

Buffer Exchange

TFF or dialysis into PBS or your preferred formulation buffer.

Documentation

Batch records, COA, QC reports, and traceability support.

Best for: lipid nanoparticle formulation, siRNA LNP, ASO LNP, mRNA encapsulation, microfluidic LNP mixing, TFF buffer exchange, and Bio-Synthesis LNP manufacturing programs.
siRNA

Small RNA LNP support

ASO

LNA / cEt compatible review

mRNA

Encapsulation and stability support

QC

DLS, EE%, zeta, LAL

From payload definition to QC-supported LNP delivery

The workflow is organized around formulation control, buffer exchange, sterile filtration or polishing, and release analytics.

1 Define Payload, dose, target size/PDI 2 Formulate microfluidic mixing FRR/TFR optimization Self-assembly lipid composition + payload ratio 3 Purify / Exchange TFF or dialysis final buffer exchange 4 Polish Sterile filtration fill-finish option 5 Test & Report EE%, DLS, zeta, reports

Process parameters are tuned around payload type, target particle size/PDI, encapsulation efficiency, lipid composition, buffer exchange, sterile filtration, and QC release criteria.

Formulation Control

  • FRR and TFR tuned for target particle size and PDI
  • Ionizable lipid, DSPC, cholesterol, and PEG-lipid composition review
  • Payload ratio optimization to support encapsulation efficiency

Buffer Exchange & Handling

  • Citrate buffer conditions for the formulation step
  • Exchange into PBS or custom final formulation buffer
  • TFF or dialysis options based on project scale

Storage & Stability Guidance

  • 2-8 °C typical for siRNA / ASO LNP programs
  • -20 to -80 °C typical for mRNA LNP programs
  • Program-dependent handling and stability support

Release analytics for particle quality, payload retention, and formulation readiness

Specifications below are examples. Final release criteria should be set by modality, dose, formulation, and regulatory context.

Attribute Typical Spec Method
Particle Size 80 ± 20 nm DLS, Z-average
PDI ≤ 0.20 DLS
Encapsulation Efficiency ≥ 85%, program-dependent Dye exclusion, such as RiboGreen
Zeta Potential Report Electrophoretic light scattering
pH / Osmolality Report / target range pH meter / osmometer
Residual Solvent Meets limits GC
Endotoxin ≤ 0.5 EU/mL LAL
Bioburden / Sterility Meets acceptance USP tests
Appearance No visible particulates Visual inspection

What to include for a faster LNP quote

Payload Details

  • Modality: siRNA, ASO, or mRNA
  • Sequence, length, chemistry, or payload file
  • Target dose, concentration, and final volume

Formulation Targets

  • Target size, such as 80 nm
  • PDI goal, such as ≤ 0.20
  • EE% goal, such as ≥ 85%
  • Preferred lipid system if known

QC & Delivery

  • Final buffer and storage condition
  • DLS, EE%, zeta, endotoxin, residual solvent
  • RUO, development, or GMP-like documentation
  • Tube, vial, or custom fill format

Ready to discuss your LNP encapsulation program?

For the fastest technical review, share your payload type, target size/PDI, encapsulation efficiency goal, final buffer, dose or concentration, storage condition, QC requirements, scale, and documentation needs.
siRNA / ASO / mRNA
Size, PDI & EE%
QC Documentation
Payload Review • Microfluidic Mixing • QC-Supported LNP Delivery

Need Formulation Guidance?

Discuss lipid composition, FRR/TFR, target size/PDI, N:P ratio, buffer exchange, sterile filtration, and stability planning.

Contact Us →

Fast Quote Checklist

Include payload, target size/PDI, EE% goal, final buffer, scale, QC panel, storage condition, and documentation needs.

Request Quote →

Frequently asked questions about LNP encapsulation

FAQ

Which payloads do you support?
Bio-Synthesis supports siRNA, ASO including LNA/cEt, and mRNA or saRNA. CRISPR gRNA/mRNA programs can be reviewed by project.
How do you control size and PDI?
We optimize FRR/TFR, lipid composition, nucleic-acid ratio, and buffer conditions during microfluidic mixing, then exchange or polish into the final buffer using TFF or dialysis.
What QC data are provided?
Typical QC includes DLS size/PDI, EE% by dye exclusion, zeta potential, pH/osmolality, endotoxin or bioburden, residual solvent, appearance, and optional stability support.
Can you support regulated workflows?
Yes. We offer RUO to GMP-like pathways with ISO-aligned QC and audit-ready documentation including batch records, COA, QC reports, and chain-of-custody traceability.

Selected LNP and analytical references

  1. mRNA LNP design and advances — Nature Reviews Materials, 2021
  2. Ionizable lipid design for siRNA LNPs — Nature Biotechnology, 2010
  3. Microfluidic mixing controls liposome/LNP size — Jahn et al., 2010
  4. Early microfluidic vesicle assembly — JACS, 2004
  5. DLS sizing and PDI standard — ISO 22412:2017
  6. RiboGreen assay for EE% / free RNA — Thermo Fisher kit page

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.